Cargando…

Molecular tumor analysis and liquid biopsy: a feasibility investigation analyzing circulating tumor DNA in patients with central nervous system lymphomas

BACKGROUND: Central nervous system lymphomas (CNSL) is a devastating disease. Currently, a confirmatory biopsy is required prior to treatment. OBJECTIVE: Our investigation aims to prove the feasibility of a minimally-invasive diagnostic approach for the molecular characterization of CNSL. METHODS: T...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hickmann, Anne-Katrin, Frick, Maximilian, Hadaschik, Dirk, Battke, Florian, Bittl, Markus, Ganslandt, Oliver, Biskup, Saskia, Döcker, Dennis
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6397454/ https://www.ncbi.nlm.nih.gov/pubmed/30823914 http://dx.doi.org/10.1186/s12885-019-5394-x

Ejemplares similares

Tumor mutation burden and circulating tumor DNA in combined CTLA-4 and PD-1 antibody therapy in metastatic melanoma – results of a prospective biomarker study
por: Forschner, Andrea, et al.
Publicado: (2019)

Circulating Tumor DNA Correlates with Outcome in Metastatic Melanoma Treated by BRAF and MEK Inhibitors – Results of a Prospective Biomarker Study
por: Forschner, Andrea, et al.
Publicado: (2020)

Clinical Applications of Cerebrospinal Fluid Circulating Tumor DNA as a Liquid Biopsy for Central Nervous System Tumors
por: Yan, Weiwei, et al.
Publicado: (2020)

Liquid biopsy for pediatric central nervous system tumors
por: Bonner, Erin R., et al.
Publicado: (2018)

Circulating tumor cells and DNA as liquid biopsies
por: Heitzer, Ellen, et al.
Publicado: (2013)

Liquid biopsy in hepatocellular carcinoma: circulating tumor cells and circulating tumor DNA
por: Ye, Qianwei, et al.
Publicado: (2019)

Case Report: Targeting of individual somatic tumor mutations by multipeptide vaccination tailored for HLA class I and II presentation induces strong CD4 and CD8 T-cell responses in a patient with metastatic castration sensitive prostate cancer
por: Zelba, Henning, et al.
Publicado: (2023)

Liquid Biopsy of Hepatocellular Carcinoma: Circulating Tumor-Derived Biomarkers
por: Yin, Chang-Qing, et al.
Publicado: (2016)

Recent Advances in Liquid Biopsy Based on Circulating Tumor DNA
por: Sakuma, Yu, et al.
Publicado: (2019)

Laser transfer for circulating tumor cell isolation in liquid biopsy
por: Molpeceres, Carlos, et al.
Publicado: (2023)

Capturing Genomic Evolution of Lung Cancers through Liquid Biopsy for Circulating Tumor DNA
por: Offin, Michael, et al.
Publicado: (2017)

Liquid biopsy in pancreatic ductal adenocarcinoma: current status of circulating tumor cells and circulating tumor DNA
por: Lee, Jee‐Soo, et al.
Publicado: (2019)

Current Status of Circulating Tumor Cells, Circulating Tumor DNA, and Exosomes in Breast Cancer Liquid Biopsies
por: Tellez-Gabriel, Marta, et al.
Publicado: (2020)

The second report of a new hypomyelinating disease due to a defect in the VPS11 gene discloses a massive lysosomal involvement
por: Hörtnagel, Konstanze, et al.
Publicado: (2016)

Tumor‐proximal liquid biopsy to improve diagnostic and prognostic performances of circulating tumor cells
por: Buscail, Etienne, et al.
Publicado: (2019)

Circulating tumor cells and extracellular vesicles as liquid biopsy markers in neuro-oncology: prospects and limitations
por: Westphal,, Manfred, et al.
Publicado: (2022)

Circulating cell-free DNA and circulating tumor cells, the “liquid biopsies” in ovarian cancer
por: Cheng, Xianliang, et al.
Publicado: (2017)

Clinical Applications of Circulating Tumor Cells and Circulating Tumor DNA as a Liquid Biopsy Marker in Colorectal Cancer
por: Heidrich, Isabel, et al.
Publicado: (2021)

Liquid Biopsy for Prognosis and Treatment in Metastatic Colorectal Cancer: Circulating Tumor Cells vs Circulating Tumor DNA
por: Patelli, Giorgio, et al.
Publicado: (2021)

Circulating tumor DNA: a promising biomarker in the liquid biopsy of cancer
por: Cheng, Feifei, et al.
Publicado: (2016)

Current Status of Circulating Tumor DNA Liquid Biopsy in Pancreatic Cancer
por: Grunvald, Miles W., et al.
Publicado: (2020)

Clinical applications of liquid biopsy as prognostic and predictive biomarkers in hepatocellular carcinoma: circulating tumor cells and circulating tumor DNA
por: Li, Jie, et al.
Publicado: (2018)

Circulating tumor DNA as a liquid biopsy target for detection of pancreatic cancer
por: Takai, Erina, et al.
Publicado: (2016)

Detection of circulating tumor cells in liquid biopsy from Ewing sarcoma patients
por: Benini, Stefania, et al.
Publicado: (2018)

Liquid Biopsy-Analysis of Circulating Tumor DNA (ctDNA) in Bladder Cancer
por: Todenhöfer, Tilman, et al.
Publicado: (2018)

The question of WGS’s clinical utility remains unanswered
por: Battke, Florian, et al.
Publicado: (2021)

Immune monitoring and TCR sequencing of CD4 T cells in a long term responsive patient with metastasized pancreatic ductal carcinoma treated with individualized, neoepitope-derived multipeptide vaccines: a case report
por: Sonntag, Katja, et al.
Publicado: (2018)

Circulating tumor DNA as an emerging liquid biopsy biomarker for early diagnosis and therapeutic monitoring in hepatocellular carcinoma
por: Wu, Xiaolin, et al.
Publicado: (2020)

Adjuvant Treatment for Breast Cancer Patients Using Individualized Neoantigen Peptide Vaccination—A Retrospective Observation
por: Zelba, Henning, et al.
Publicado: (2022)

Liquid biopsy and therapeutic response: Circulating tumor cell cultures for evaluation of anticancer treatment
por: Khoo, Bee Luan, et al.
Publicado: (2016)

Techniques of using circulating tumor DNA as a liquid biopsy component in cancer management
por: Elazezy, Maha, et al.
Publicado: (2018)

Circulating Tumor DNA Analysis for Liver Cancers and Its Usefulness as a Liquid Biopsy
por: Ono, Atsushi, et al.
Publicado: (2015)

The new horizon of liquid biopsy in sarcoma: the potential utility of circulating tumor nucleic acids
por: Wei, Junqiang, et al.
Publicado: (2020)

Liquid Biopsy from Bile-Circulating Tumor DNA in Patients with Biliary Tract Cancer
por: Han, Jin-Yi, et al.
Publicado: (2021)

Liquid Biopsy Using Cell-Free or Circulating Tumor DNA in the Management of Hepatocellular Carcinoma
por: Lyu, Xueying, et al.
Publicado: (2022)

Validation of a liquid biopsy assay with molecular and clinical profiling of circulating tumor DNA
por: Finkle, Justin D., et al.
Publicado: (2021)

Mutated circulating tumor DNA as a liquid biopsy in lung cancer detection and treatment
por: Filipska, Martyna, et al.
Publicado: (2021)

Circulating tumor cells and cell-free tumor DNA analyses in urothelial cancer using the LiquidBiopsy platform
por: Kobayashi, Minoru, et al.
Publicado: (2022)

Liquid biopsies for liquid tumors: emerging potential of circulating free nucleic acid evaluation for the management of hematologic malignancies
por: Hocking, Jay, et al.
Publicado: (2016)

Liquid Biopsy and Primary Brain Tumors
por: Eibl, Robert H., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_9pbd4lae4siooo5860okv8mio3